QIAGEN Launches Streamlined Bioinformatics for RNA Sequencing of Liquid Biopsies

Friday, April 15, 2016 Genetics & Stem Cells News J E 4
RNA-seq Explorer Solution generates clear insights for cancer 'omics' analyses

HILDEN, Germany and GERMANTOWN, Maryland, April 14, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of "omics" data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis™, Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.

"The RNA-seq Explorer Solution provides the most powerful bioinformatics tool for the analysis and interpretation of RNA sequencing data from liquid biopsies, including from tumor-derived exosomes. Next-generation sequencing of liquid biopsies, one of the most promising new ways of detecting and characterizing cancer, demands the highest-accuracy tools to make sense of inherently noisy data," said Dr. Laura Furmanski, Senior Vice President and head of QIAGEN's Bioinformatics Business Area. "QIAGEN's streamlined RNA solution transforms raw data from liquid biopsies into valuable insights - a significant milestone for liquid biopsy analysis of indications such as cancer. The best bioinformatics will drive progress in precision medicine and cancer management."

Click here for full press release.

Public Relations:

Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 Email:

Investor Relations:

John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Aratana Therapeutics to Report First Quarter 2016 ...
Cooper 93.5 to Raise Money for the ADA